Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRICKET: Cetuximab Rechallenge in mCRC
NCT02296203Phase 2Unknown
- Sponsor
- Gruppo Oncologico Nord Ovest
- Start
- Oct 2014
- Primary completion
- Jun 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in metastatic colorectal cancer (mCRC), sponsored by Gruppo Oncologico Nord Ovest. Status: unknown.
02
Drugs
cetuximab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02296203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02296203.